Biomea Fusion receives FDA IND clearance for BMF-219 in type 2 diabetes; expands COVALENT-111 to US sites

Biomea Fusion, Inc.

FDA cleared IND for BMF-219 (covalent menin inhibitor) in type 2 diabetes; will activate US sites in ongoing COVALENT-111 study.
Phase I portion completed with favorable safety, PK, and PD profile.
Phase II portion evaluating BMF-219's ability to restore beta-cell health and long-term glycemic control.
Initial Phase II data expected in first half of 2023.
Company to host investor conference call on December 15, 2022 at 4 PM EST.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.